🟢 Telix Pharmaceuticals is trading 5.4% up in pre-market with no confirmed catalyst

Telix Pharmaceuticals is trading at $11.32, up 5.39% pre-market; no confirmed catalyst directly explains the move.

• On October 19, 2026, Telix announced a collaboration with Ekalia to develop U.S. astatine-211 production, including a planned first installation at its Trevose site.
• The partnership could support its alpha-therapy pipeline; no operational production is reported, and Telix did not say it drove the move.
• Market context is mixed, without a clear same-direction broad-market rally; pre-market volume and activity details are unavailable.